about
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsParkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathyIdentification of a Japanese family with LRRK2 p.R1441G-related Parkinson's diseaseParkin disease: a clinicopathologic entity?Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.DJ-1, PINK1, and their effects on mitochondrial pathwaysParkinson's disease: insights from pathways.Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation.Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease.Role of LRRK2 kinase dysfunction in Parkinson diseaseUnravelling the role of defective genes.Leucine-rich repeat kinase 2 for beginners: six key questions.N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.Evolution of neurodegeneration.The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's diseaseMechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.α-Synuclein oligomers and clinical implications for Parkinson disease.Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Genetic variants in diseases of the extrapyramidal system.A tangled web - tau and sporadic Parkinson's diseaseParkinson's disease mouse models in translational research.Genes associated with Parkinson's disease: regulation of autophagy and beyond.Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains.Rafts, Nanoparticles and Neural DiseasePotential Biomarkers of the Earliest Clinical Stages of Parkinson's Disease.LRRK2 dephosphorylation increases its ubiquitination.Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease.Alpha-synuclein oligomers: a new hope.Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson's Disease?ER-mitochondria signaling in Parkinson's disease.Modification of α-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: its relevance to Parkinson disease.
P2860
Q27013695-014BEDBE-1A94-4AA5-9A69-9CF033BED857Q28475940-7092E68A-DE35-4B4E-B58D-DBB7DC01B3C6Q30587398-C2896E16-2353-4C3C-90ED-BDF9071D2997Q30594306-D3982B07-C395-454F-902B-9AB7BE866045Q31028020-83F34057-E05A-4B87-93FA-ADE2421D920AQ33727623-856ABFDB-2469-49A8-B2A4-121309257AF1Q33733264-25B7148C-DD18-49BC-87D2-E423A3C6167DQ33871291-8ED57DC1-4157-4992-875F-5BEF081FF43EQ33948478-4B846FA7-B72E-4E39-8810-2DC13EBDF549Q33997655-0EBAA123-AE5F-468B-AB3F-290496D0C6EAQ34192817-EDED3006-A2CC-44F9-83E6-92A6766B1261Q34201811-330F30AE-6271-4B72-82F5-1D93C3F02542Q34259058-393A2E97-4E1F-48EE-BF1F-5BE4A566723AQ35193829-C371D854-8CA3-4D40-BB43-A6DCC6B11BD6Q36325667-07F42871-B33F-4C81-832C-A611FA04E66BQ36325701-5360EAB2-294F-4B6B-9E15-5D8A2E117B41Q36325784-1E233044-2AF7-47F3-84A9-3B5861ED1414Q36379938-7AFADF78-FF77-4AB2-AA13-C58B6C1A83F9Q36718306-81F98DC1-1826-4845-A167-9447895C421FQ37119983-9513A022-C246-4D2A-81B8-06A965A0455AQ37225356-1E0B2B2A-3A67-4919-A170-29AEFC19FCCBQ37513500-24615E64-9AE9-44B2-BD0F-B85B95677E27Q37645614-F3D63687-1F4D-4D35-A583-884F7405EF03Q37855547-552BB1C5-967B-417A-BB19-1D70B7141660Q37874160-E3F28880-D46D-4125-B653-0F18E254AE74Q38557027-733D4C32-6A14-492D-B105-4C79CE4E90E3Q38819135-584458B2-0A49-4EB9-BC57-BC532F770A22Q39203564-8D9DEC5F-DB4C-4BC6-9D89-099847A19865Q41385214-3DC8AB0C-513B-4D9F-9C30-5A6EE4A2C5E5Q41785779-DAF98191-3F15-448F-B1AD-6EB20F7115A5Q41954719-EA9A2C66-7B51-4900-B1BD-692513F13F28Q46321755-BC20BFB4-018A-4E67-BCBA-EDC2AD6CDFADQ47239603-590EEDE7-3758-43FC-9FC6-71D4024E60ABQ54987116-80597690-654B-4C2B-94A5-DDE3A56D9CC8Q55250469-B362DCC6-23EA-4897-8733-3A6B462C2E8C
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Genetic neuropathology of Parkinson's disease.
@ast
Genetic neuropathology of Parkinson's disease.
@en
Genetic neuropathology of Parkinson's disease.
@nl
type
label
Genetic neuropathology of Parkinson's disease.
@ast
Genetic neuropathology of Parkinson's disease.
@en
Genetic neuropathology of Parkinson's disease.
@nl
prefLabel
Genetic neuropathology of Parkinson's disease.
@ast
Genetic neuropathology of Parkinson's disease.
@en
Genetic neuropathology of Parkinson's disease.
@nl
P2093
P2860
P1476
Genetic neuropathology of Parkinson's disease
@en
P2093
John Hardy
Mark R Cookson
Patrick A Lewis
P2860
P304
P577
2008-01-01T00:00:00Z